Search

Search results

4466 results found

Join the Lab

Page

Welcome! Please contact Veronique, including sending your curriculum vitae, a brief statement of research experience and interests, and letters of reference. Email: vanderhorstlab@bidmc.harvard.edu

Celada M, Zaarour N, Cheung J, Gross C, Lim A, Buchman AS, Saberi P, Varma G, VanderHorst V. Standardization of postmortem human brainstem along the rostrocaudal axis to accommodate for inter-specimen structural heterogeneity. Sci Rep. 2025 Oct 15;15(1):36064. doi: 10.1038/s41598-025-20016-7.PMID...

BIDMC Mass Spectrometry Core Enables Discovery of TRIDENT, a New Driver of Drug Resistance in Lung Cancer

News: November 24, 2025

A recent PNAS publication from Dr. Frank Slack’s group uncovers TRIDENT, an EGFR-induced long non-coding RNA that plays a key role in tumor growth and chemoresistance in non–small cell lung cancer (NSCLC). The team shows that TRIDENT activates TRIM28-mediated DNA damage repair, allowing cancer cells...

Leadership & Staff

Page

Daniela Garcia Perez, MD

Person:

Bogota, Columbia Medical School Universidad de Los Andes Facultad de Medicina, Columbia Undergraduate Universidad de Los Andes

Xiaohui Li, PhD

Person: Postdoc Research Fellow

Xiaohui studies the crosstalk among metabolism, epigenetic mechanisms, and DNA damage response. She brings extensive experience in imaging, biochemistry, and in vitro neuronal culture systems. Xiaohui's project focuses on the epigenetic mechanism in breast cancer and glioma. Ph.D. : University of...

Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity.

Publication: Journal Article

Munroe, Melissa E, Kendra Young, Rufei Lu, Joel M Guthridge, Diane L Kamen, Gary S Gilkeson, Michael H Weisman, et al. 2025. “Dysregulated Soluble Immune Mediators and Lupus-Associated Autoantibody Specificities Inform the Development of Immune Indexes That Characterise Classified SLE Transition and SLE Disease Activity.”. Lupus Science & Medicine 12 (2).

IL-17+/IL-10+ Ratio in TCRαβ+ CD4- CD8- T Cells As a Marker of Disease Activity in Lupus-Prone Mice and Patients With Systemic Lupus Erythematosus.

Publication: Journal Article

Imai, Rui, Yi Li, Hao Li, Anwesha Kar, Rong Fu, Wei Li, Vasileios C Kyttaris, and George C Tsokos. 2025. “IL-17+/IL-10+ Ratio in TCRαβ+ CD4- CD8- T Cells As a Marker of Disease Activity in Lupus-Prone Mice and Patients With Systemic Lupus Erythematosus.”. ACR Open Rheumatology 7 (10): e70108.

Interleukin-23 receptor deficiency in podocytes averts the development of lupus nephritis.

Publication: Journal Article

Fu, Rong, Afroditi Boulougoura, Shuilian Yu, Hao Li, Wenliang Pan, Yushiro Endo, Rhea Bhargava, et al. 2025. “Interleukin-23 Receptor Deficiency in Podocytes Averts the Development of Lupus Nephritis.”. Arthritis & Rheumatology (Hoboken, N.J.).

ADAM9 Promotes Glycolysis in Th17 Cells and Autoimmunity Through Activation of IGF-1 Signaling.

Publication: Journal Article

Karino, Kohei, Masataka Umeda, Theodoros Vichos, Wenliang Pan, Michihito Kono, Maria G Tsokos, and George C Tsokos. 2025. “ADAM9 Promotes Glycolysis in Th17 Cells and Autoimmunity Through Activation of IGF-1 Signaling.”. Arthritis & Rheumatology (Hoboken, N.J.).